ProQR director reports option holdings

ProQR Therapeutics N.V. director Alison Frances Lawton filed an initial ownership report listing multiple share option awards over Ordinary Shares.

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director Alison Frances Lawton filed an initial ownership report listing multiple share option awards over Ordinary Shares. These options have exercise prices ranging from 1.9800 to 15.7800 and expiration dates between 2026 and 2035, all held directly.

Footnotes explain that some options are fully vested, while others vest over time. For several grants, 25% of the shares vest on January 1 of 2024, 2025, 2026, or 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service to the company.

Insider Trade Summary

11 transactions reported

Mixed 11 txns

Insider Lawton Alison Frances

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 245,599 contracts (Direct)

Footnotes (5)

1. F1. Fully vested.
2. F2. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
3. F3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
4. F4. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
5. F5. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ProQR (PRQR) Form 3 filing for Alison Frances Lawton show?

The Form 3 shows Alison Frances Lawton’s initial beneficial ownership in ProQR through multiple share option awards over Ordinary Shares, all held directly, with specified exercise prices, expiration dates, and detailed vesting schedules tied to continued service.

Are Alison Lawton’s ProQR (PRQR) share options fully vested?

Some ProQR share options held by Alison Lawton are fully vested, while others vest over time. Several grants vest 25% on January 1 of 2024, 2025, 2026, or 2027, with the remaining 75% vesting in 12 quarterly installments, subject to continuous service.

What are the vesting terms for Alison Lawton’s ProQR (PRQR) options?

For multiple option grants, 25% of the shares vest and become exercisable on January 1 of 2024, 2025, 2026, or 2027. The remaining 75% then vest in 12 substantially equal quarterly installments, contingent on Alison Lawton’s continuous service to ProQR.

What exercise price range is disclosed for ProQR (PRQR) options held by Alison Lawton?

The filing lists several direct share option positions with exercise prices including 1.9800, 2.0200, 2.6500, 3.3000, 3.4100, 4.2000, 4.8900, 4.9000, 8.0100, 9.9100, and 15.7800, each tied to specific expiration dates between 2026 and 2035.

When do Alison Lawton’s ProQR (PRQR) options expire?

The disclosed share options over ProQR Ordinary Shares have staggered expiration dates, including June 20, 2026, December 31 of 2026, 2027, 2028, 2029, 2030, 2032, 2033, 2034, and 2035, reflecting a long-dated incentive structure for the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lawton Alison Frances

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

3a. Foreign Trading Symbol
[N/A]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(1)	06/20/2026	Ordinary Shares	5,815	$4.89	D
Share Option (Right to Buy)	(1)	12/31/2026	Ordinary Shares	32,164	$4.9	D
Share Option (Right to Buy)	(1)	12/31/2027	Ordinary Shares	27,500	$3.3	D
Share Option (Right to Buy)	(1)	12/31/2028	Ordinary Shares	14,918	$15.78	D
Share Option (Right to Buy)	(1)	12/31/2029	Ordinary Shares	24,615	$9.91	D
Share Option (Right to Buy)	(1)	12/31/2030	Ordinary Shares	23,239	$4.2	D
Share Option (Right to Buy)	(1)	02/29/2032	Ordinary Shares	23,931	$8.01	D
Share Option (Right to Buy)	(2)	12/31/2032	Ordinary Shares	22,608	$3.41	D
Share Option (Right to Buy)	(3)	12/31/2033	Ordinary Shares	23,489	$1.98	D
Share Option (Right to Buy)	(4)	12/31/2034	Ordinary Shares	22,128	$2.65	D
Share Option (Right to Buy)	(5)	12/31/2035	Ordinary Shares	25,192	$2.02	D

Explanation of Responses:

1. Fully vested.

2. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

4. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

5. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)